Search
Kidney
EAY191-E4 **11/30/23: EAY191-E4 is nearing the completion of its first stage of accrual, and no additional treatment assignments will be processed** **If biopsy needed, TBD at MBMC**
ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors
AFT-63 **Only Cohort C Open – Non-lung Cancer: Renal Cancer and Stomach Cancer (including lower esophagus)**
DNA Evaluation of Fragments for Early Interception – Lung Cancer Training Study (DELFI-L101 Study)
EAY191 (ComboMATCH) **If biopsy needed, TBD at MBMC**
Molecular Analysis for Combination Therapy Choice
S2200 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)
ALLIANCE A212102 **AT MBMC ONLY** **As of 8/1/23 the following Healthy Control Cohorts are Open (all others are Closed as of 2/22/23): Non-White Male Participants Age 60 or More Without Cancer Diagnosis and Non-White Male Participants Under Age 60 Without Cancer Diagnosis** **Effective with the release of Update #02, enrollment to the thyroid, melanoma, and sarcoma cancer cohorts has been closed.**
Blinded Reference Set For Multicancer Early Detection Blood Tests
URCC 19075 **MBMC ONLY**
Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)
URCC-21038
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
S1931
Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
URCC 18007
Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue
A031704
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
